Results 91 to 100 of about 16,198,215 (212)

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, Volume 121, Issue 11, Page 3010-3024, November 2026.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source

The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study

Neuropsychiatric Disease and Treatment, 2017
Tea Rosic,1 Leen Naji,2 Monica Bawor,3 Brittany B Dennis,3 Carolyn Plater,4 David C Marsh,5 Lehana Thabane,6–8 Zainab Samaan6–11 1St Joseph’s Healthcare, 2Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada;
Rosic T, Naji L, Bawor M, Dennis BB, Plater C, Marsh DC, Thabane L, Samaan Z   +7 more
doaj  

Determinants of Opioid use disorder severity and relapse among the Egyptian population: findings from a cohort study

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Background Opioid use disorder (OUD) is characterized by features that influence its progression, severity, and relapse risk. Clinical criteria classify Severity as mild, moderate, or severe.
Amira A. Abdelnoor, Mostafa M. Kamel, Fatma M. Elgazzar   +2 more
doaj   +1 more source

Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation

Addiction, Volume 121, Issue 11, Page 3040-3052, November 2026.
Abstract Aims To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative ...
Vivienne Y. Zhou, Nadia Fairbairn, Jingxin Lei, Rupinder Brar, Paxton Bach, M. Eugenia Socias   +5 more
wiley   +1 more source

Antepartum multidisciplinary approach improves postpartum pain scores in patients with opioid use disorder

Journal of Perinatal Medicine
Pregnancies affected by opioid use disorder (OUD) face difficulties with postpartum pain control. This study aims to determine if prenatal anesthesia consultation for patients on medication for opioid use disorder (MOUD) affects maternal postpartum pain ...
Yang Tiffany, Stetler Emily, Garretto Diana, Herrera Kimberly, Garry David, Heiselman Cassandra   +5 more
doaj   +1 more source

US opioid crisis : addressing maternal and infant health [PDF]

Opioid use disorder (OUD) can cause many negative health outcomes for mothers and their babies, both during pregnancy and after delivery. Infants can be born with breathing and feeding problems, and mothers are at risk of opioid-related overdoses.

core  

Enhancing outcomes in opioid use disorder treatment: an economic evaluation of improving medication adherence for buprenorphine through blister-packaging.

BACKGROUND The opioid epidemic has severely impacted the US over the last 15 years. Buprenorphine is a partial opioid agonist indicated for the treatment of opioid use disorder (OUD) and is recognized as an effective treatment when taken as prescribed ...
Lucaci, Julia D, Dumitru, Doina, Saad, Peter, Barnes, Nathan E, Borrelli, Eric P, Nelkin, Heather   +5 more
core   +1 more source

Characterizing complex opioid use disorder care trajectories and outcomes following acute service utilization: A protocol for a population-based data linkage study.

PLoS ONE
Despite robust evidence that medications for opioid use disorder (MOUD) reduce overdose and mortality, substantial care gaps remain following opioid-related hospital encounters.
Noa Krawczyk, Ignacio Bórquez, Megan Miller, Sung Woo Lim, Teena Cherian, Daniel Schatz, Alex Harocopos, Emily Carter, Marc Scott, Brandy F Henry, David Frank, Magdalena Cerdá, Arthur Robin Williams   +12 more
doaj   +1 more source

Clinical applications of wearable devices for individuals with at‐risk substance use and substance use disorders: A systematic review

The American Journal on Addictions, Volume 35, Issue 6, Page 702-726, November 2026.
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas, Matthew E. Sloan, Yaoyi Xing, Ethan Kim, Dhvani Mehta, Anna Mouzenian, Lena C. Quilty, Jeffrey D. Wardell, Shannon Lange, Daniel Felsky, Victor M. Tang   +10 more
wiley   +1 more source

Understanding the association between medical mistrust, opioid knowledge, and stigma towards adults with a history of an opioid use disorder

Background: Negative public attitudes or stigma towards opioid use disorder (OUD) is associated with lower engagement in treatment for OUD. Studies examining correlates of opioid-related stigma are needed to better understand modifiable pathways to be ...
Flanagan, Elizabeth, Schneider, John, Taylor, Bruce G., Aalsma, Matthew C., Borowiecki, Mateusz, Adams, Zachary W., Lamuda, Phoebe A., Dellucci, Trey V., Pollack, Harold   +8 more
core   +1 more source